CYCN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CYCN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cyclerion Therapeutics's EBITDA for the three months ended in Mar. 2024 was $-1.62 Mil. Cyclerion Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Cyclerion Therapeutics's EBITDA margin for the quarter that ended in Mar. 2024 was 0.00%.
The historical data trend for Cyclerion Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclerion Therapeutics Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
EBITDA Margin % | Get a 7-Day Free Trial | -2,714.38 | -3,512.06 | -1,621.75 | -6,220.54 | - |
Cyclerion Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
EBITDA Margin % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Cyclerion Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Cyclerion Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Cyclerion Therapeutics's EBITDA Margin % falls into.
EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.
Cyclerion Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as
Cyclerion Therapeutics's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclerion Therapeutics (NAS:CYCN) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Thank you for viewing the detailed overview of Cyclerion Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Terrance Mcguire | director | C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154 |
Steven Hyman | director | C/O VOYAGER THERAPEUTICS, INC., 75 SIDNEY STREET, CAMBRIDGE MA 02139 |
Andreas Busch | officer: Chief Scientific Officer | C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142 |
George H Conrades | director | 500 TECHNOLOGY SQUARE, FIFTH FLOOR, CAMBRIDGE MA 02139 |
Stephanie Lovell | director | C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142 |
Ole Isacson | director | CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142 |
Kevin Churchwell | director | C/O CYCLERION THERAPEUTICS, CAMBRIDGE MA 02142 |
Michael Mendelsohn | director | C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142 |
Peter M Hecht | director, officer: Chief Executive Officer | C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142 |
Slate Path Capital Lp | 10 percent owner | 717 5TH AVENUE, 16TH FL., NEW YORK NY 10022 |
Errol B Desouza | director | 215 COLLEGE ROAD, PARAMUS NJ 07652 |
Anjeza Gjino | officer: Chief Financial Officer | C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142 |
Christopher I Wright | officer: Chief Medical Officer | C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142 |
Cheryl Gault | officer: Chief Operating Officer | CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142 |
Mark G Currie | officer: President and CSO | C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142 |
From GuruFocus
By PurpleRose PurpleRose • 08-09-2022
By sperokesalga sperokesalga • 03-27-2023
By GuruFocusNews GuruFocusNews • 07-10-2022
By Value_Insider Value_Insider • 11-22-2022
By GuruFocusNews GuruFocusNews • 06-22-2022
By PurpleRose PurpleRose • 07-26-2022
By GuruFocusNews GuruFocusNews • 02-23-2022
By sperokesalga sperokesalga • 05-11-2023
By GuruFocusNews GuruFocusNews • 02-24-2022
By sperokesalga sperokesalga • 03-22-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.